Seaport Therapeutics Insider Trades
NASDAQ: SPTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 2 · $20.04M
- Sales
- 0 · $0
- Shares bought / sold
- 1.11M / 0
- Net activity
- Net buying $20.0 million
Seaport Therapeutics insider activity
Over the last 12 months, Seaport Therapeutics insiders reported 15 transactions on SEC Form 4: 2 open-market purchases and 0 sales. Insiders bought $20.0 million and sold $0 worth of stock, for net insider buying of $20.0 million. The most recent filing shows HOMBACH ROBERT J. (Director) buying 13,000 shares at $18.14 on Jun 22, 2026.
Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put SPTX's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
SPTX insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 22, 2026 | HOMBACH ROBERT J.Director | Buy | 13,000 | $235.77K | Form 4 |
| May 4, 2026 | Loebel AntonyChief Medical Officer | Conversion | 20,109 | — | Form 4 |
| May 4, 2026 | ARCH Venture Partners XII, LLC & ARCH Venture Partners XII, L.P. & ARCH Venture Fund XII, L.P. & CRANDELL KEITH & NELSEN ROBERT & Burow Kristina & GILLIS STEVEN10% Owner | Buy | 1,100,000 | $19.80M | Form 4 |
| May 4, 2026 | ARCH Venture Partners XII, LLC & ARCH Venture Partners XII, L.P. & ARCH Venture Fund XII, L.P. & CRANDELL KEITH & NELSEN ROBERT & Burow Kristina & GILLIS STEVEN10% Owner | Conversion | 2,681,265 | — | Form 4 |
| May 4, 2026 | ARCH Venture Partners XII, LLC & ARCH Venture Partners XII, L.P. & ARCH Venture Fund XII, L.P. & CRANDELL KEITH & NELSEN ROBERT & Burow Kristina & GILLIS STEVEN10% Owner | Conversion | 2,513,686 | — | Form 4 |
| May 4, 2026 | Gladstein LanaGeneral Counsel | Conversion | 33,515 | — | Form 4 |
| May 4, 2026 | Torres DeniceDirector | Conversion | 13,406 | — | Form 4 |
| May 4, 2026 | PAUL STEVEN MDirector | Conversion | 67,031 | — | Form 4 |
| May 4, 2026 | Chen Michael CunyuanChief Scientific Officer | Conversion | 3,351 | — | Form 4 |
| May 4, 2026 | HEALY JAMESDirector | Conversion | 804,379 | — | Form 4 |
| May 4, 2026 | HEALY JAMESDirector | Conversion | 1,927,159 | — | Form 4 |
| May 4, 2026 | White LaurenChief Financial Officer | Conversion | 6,702 | — | Form 4 |
| May 4, 2026 | PureTech Health plc & PureTech LYT, Inc.10% Owner | Conversion | 965,255 | — | Form 4 |
| May 4, 2026 | PureTech Health plc & PureTech LYT, Inc.10% Owner | Conversion | 2,681,265 | — | Form 4 |
| May 4, 2026 | PureTech Health plc & PureTech LYT, Inc.10% Owner | Conversion | 12,736,014 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4